References

Unmet clinical needs and management recommendations for blastic plasmacytoid dendritic cell neoplasm: a consensus-based position paper from an ad hoc international expert panel

10.1097/hs9.0000000000000841 · 2023 · External reference

Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study

10.3324/haematol.2012.072645 · 2013 · External reference

Epidemiology and survival outcomes in blastic plasmacytoid dendritic cell neoplasm (BPDCN): a US population-based study

10.1182/blood-2023-191150 · 2023 · External reference

Therapeutic approaches for blastic plasmacytoid dendritic cell neoplasm: allogeneic hematopoietic cell transplantation and novel therapies

10.2991/chi.d.190218.001 · 2019 · External reference

Blastic plasmacytoid dendritic cell neoplasms: results of an international survey on 398 adult patients

10.1182/bloodadvances.2020002474 · 2020 · External reference

Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis

10.1182/bloodadvances.2023011308 · 2023 · External reference

Blastic plasmacytoid dendritic cell neoplasm: emerging developments and special considerations for 2023

2023 · External reference

Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm

10.1056/nejmoa1815105 · 2019 · External reference

Azacitidine and venetoclax in previously untreated acute myeloid leukemia

10.1056/nejmoa2012971 · 2020 · External reference

Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: a nonrandomized phase 2 trial

10.1001/jamaoncol.2021.1649 · 2021 · External reference

Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia

10.1158/2159-8290.cd-16-0313 · 2016 · External reference

Azacitidine and venetoclax in previously untreated acute myeloid leukemia

10.1056/nejmoa2012971 · 2020 · External reference

Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to venetoclax

10.1158/2159-8290.cd-16-0999 · 2017 · External reference

Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies

10.1002/ajh.25000 · 2018 · External reference

Venetoclax and hypomethylating agents in older/unfit patients with blastic plasmacytoid dendritic cell neoplasm

10.1002/ajh.26417 · 2022 · External reference

More on blastic plasmacytoid dendritic-cell neoplasms

10.1056/nejmc1814963 · 2019 · External reference

TET2 truncating mutations predict a worse outcome in blastic plasmacytoid dendritic cell neoplasm

10.1182/bloodadvances.2022007879 · 2023 · External reference

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: Position on standards of care and areas of need

10.1182/blood.2022017865 · 2023 · External reference

Blastic plasmacytoid dendritic cell neoplasm: a comprehensive review in pediatrics, adolescents, and young adults (AYA) and an update of novel therapies

10.1038/s41375-023-01968-z · 2023 · External reference

Diagnosing and treating blastic plasmacytoid dendritic cell neoplasm in a resource-limited setting

2024 · External reference

Unmet clinical needs and management recommendations for blastic plasmacytoid dendritic cell neoplasm: a consensus-based position paper from an ad hoc international expert panel

10.1097/hs9.0000000000000841 · 2023 · External reference

Organ involvement in adults with BPDCN is associated with sun exposure history, TET2 and RAS mutations, and survival

10.1182/bloodadvances.2024012797 · 2024 · External reference

Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target

10.3324/haematol.2018.202093 · 2019 · External reference

Blastic plasmacytoid dendritic cell neoplasm: the first report of two cases treated by 5-azacytidine

10.1111/ejh.12294 · 2014 · External reference

DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance

10.1172/jci128571 · 2019 · External reference